| Business Summary | | Digene
Corporation
develops,
manufactures
and
markets
proprietary
DNA
and
RNA
testing
systems
for
the
screening,
monitoring
and
diagnosis
of
human
diseases.
The
Company
has
developed
and
is
commercializing
its
patented
Hybrid
Capture
Gene
Analysis
System
and
tests
in
three
areas:
women's
cancers
and
infectious
diseases,
blood
viruses,
and
genomics
and
pharmaceutical
research.
The
Company's
lead
product,
the
Hybrid
Capture
II
HPV
Test,
is
the
only
FDA-approved
test
for
the
detection
of
human
papillomavirus
(HPV),
which
is
the
cause
of
greater
than
99%
of
cervical
cancer
cases.
In
addition,
Digene
has
developed
and
launched
tests
internationally
for
the
detection
and
viral
load
monitoring
of
major
blood
viruses,
including
cytomegalovirus
and
hepatitis
B
virus,
and
tests
for
the
detection
of
two
of
the
most
common
sexually
transmitted
infections,
chlamydia
and
gonorrhea. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Digene
Corporation
develops,
manufactures
and
market
proprietary
DNA
and
RNA
testing
systems
for
the
screening,
monitoring
and
diagnosis
of
human
disease.
For
the
fiscal
year
ended
6/30/01,
total
revenues
increased
48%
to
$34.2
million.
Net
loss
decreased
4%
to
$6.5
million.
Revenues
reflect
higher
sales
of
HPV
tests
and
related
equipment.
Lower
loss
was
partially
offset
by
lower
margins
due
to
facility
relocation
and
product
mix,
and
increased
personnel
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Evan Jones, 43 CEO
and Chairman | $322K | $1.5M | Charles Fleischman, 42 Pres,
COO and Chief Financial Officer | 328K | 4.1M | Robert Lilley, 55 Sr.
VP, Global Sales and Marketing | 347K | 559K | Attila Lorincz, Ph.D., 45 Sr.
VP and CSO | 252K | 2.1M | Joseph Slattery, 35 VP-Fin. | -- | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|